Investors

Press Releases

 
Press Releases
  Date Title View
Sep 9, 2010
DURHAM, NC (September 9, 2010) – The N.C. Department of Labor honored drug discovery and development company SCYNEXIS Inc. as a participant in the Safety and Health Achievement Recognition Program (SHARP). The program recognizes companies for a commitment to the safety and health of their employees. Labor Commiss...
Jul 26, 2010
Research Triangle Park, NC (July 26, 2010) - Discovery of Novel Orally Bioavailable Oxaborole 6-carboxamides that Demonstrate Cure in a Murine Model of Late Stage Central Nervous System African Trypanosomiasis Bakela Nare, Stephen Wring, Cyrus Bacchi, Beth Beaudet, Tana Bowling, Reto Brun, Daitao Chen, Charles Ding, Yv...
May 19, 2010
RESEARCH TRIANGLE PARK, NC, and KING OF PRUSSIA, PA (May 19, 2010) – SCYNEXIS, Inc. a drug discovery and development company, and Trevena, Inc., a leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today that they have entered into an agreement in which SCYNEXIS will pr...
Apr 16, 2010
RESEARCH TRIANGLE PARK, N.C. – April 16, 2010 – Drug discovery company SCYNEXIS, Inc. today presented results from two separate studies of SCY-635—a novel, oral cyclophilin inhibitor being studied for the treatment of hepatitis C virus (HCV) infection—at the 45th Annual Meeting of the European Associati...
Apr 15, 2010
RESEARCH TRIANGLE PARK, N.C.- April 15, 2010 – Drug discovery company SCYNEXIS, Inc. today presented data supporting an impressive resistance profile for SCY-635-a novel, oral cyclophilin inhibitor being studied for the treatment of hepatitis C virus (HCV) infection. In the study, SCYNEXIS demonstrated that the hepatitis...
Apr 5, 2010
RESEARCH TRIANGLE PARK, N.C. – April 5, 2010 – Drug discovery company, SCYNEXIS, Inc. today announced that multiple abstracts related to the Company’s cyclophilin inhibitor, SCY-635, were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vien...
Mar 30, 2010
RESEARCH TRIANGLE PARK, N.C. – March 30, 2010 – Drug discovery company, SCYNEXIS, Inc. announced today that management will present an overview on the Company’s lead anti-hepatitis C virus (HCV) candidate, SCY-635, at the upcoming Canaccord Adams’ Hepatitis C Conference on Thursday, April 1, 2010 at 11:...
Mar 24, 2010
RESEARCH TRIANGLE PARK, NC (May 24, 2010) – Drug discovery and development company SCYNEXIS on Thursday will lead a discussio...
Dec 17, 2009
RESEARCH TRIANGLE PARK, N.C., (Dec. 17, 2009) – Drug discovery and development company SCYNEXIS, Inc. announced today that it has achieved a third milestone in its collaboration with Merck & Co., Inc. to develop novel antifungal agents. This latest milestone payment was triggered following the initiation of clinical ...
Dec 16, 2009
RESEARCH TRIANGLE PARK, N.C. (Dec. 16, 2009) SCYNEXIS, Inc., a fully integrated drug discovery and development company, today announced that the U.S. Food and Drug Administration (FDA) completed its cGMP compliance inspection of the SCYNEXIS Process Chemistry, Analytical and Manufacturing facilities. The FDA performed both a g...
FirstPrevious ...
12
NextLast
= add release to Briefcase